Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Immune Checkpoint Inhibitors Market

ID: MRFR/HC/14661-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

US Immune Checkpoint Inhibitors Market Research Report Information By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor), By Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, and Others) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Immune Checkpoint Inhibitors Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Oncology
  50.     4.1.2 Autoimmune Disorders
  51.     4.1.3 Infectious Diseases
  52.     4.1.4 Transplant Rejection
  53.     4.1.5 Other Applications
  54.   4.2 Healthcare, BY Mechanism of Action (USD Billion)
  55.     4.2.1 CTLA-4 Inhibitors
  56.     4.2.2 PD-1 Inhibitors
  57.     4.2.3 PD-L1 Inhibitors
  58.     4.2.4 Combination Therapies
  59.     4.2.5 Other Mechanisms
  60.   4.3 Healthcare, BY Route of Administration (USD Billion)
  61.     4.3.1 Intravenous
  62.     4.3.2 Subcutaneous
  63.     4.3.3 Oral
  64.     4.3.4 Intramuscular
  65.     4.3.5 Other Routes
  66.   4.4 Healthcare, BY Patient Demographics (USD Billion)
  67.     4.4.1 Age Groups
  68.     4.4.2 Gender
  69.     4.4.3 Ethnicity
  70.     4.4.4 Comorbidities
  71.     4.4.5 Socioeconomic Status
  72.   4.5 Healthcare, BY Treatment Setting (USD Billion)
  73.     4.5.1 Hospital
  74.     4.5.2 Outpatient Clinic
  75.     4.5.3 Home Care
  76.     4.5.4 Research Institutions
  77.     4.5.5 Other Settings
  78. 5 SECTION V: COMPETITIVE ANALYSIS
  79.   5.1 Competitive Landscape
  80.     5.1.1 Overview
  81.     5.1.2 Competitive Analysis
  82.     5.1.3 Market share Analysis
  83.     5.1.4 Major Growth Strategy in the Healthcare
  84.     5.1.5 Competitive Benchmarking
  85.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  86.     5.1.7 Key developments and growth strategies
  87.       5.1.7.1 New Product Launch/Service Deployment
  88.       5.1.7.2 Merger & Acquisitions
  89.       5.1.7.3 Joint Ventures
  90.     5.1.8 Major Players Financial Matrix
  91.       5.1.8.1 Sales and Operating Income
  92.       5.1.8.2 Major Players R&D Expenditure. 2023
  93.   5.2 Company Profiles
  94.     5.2.1 Bristol-Myers Squibb (US)
  95.       5.2.1.1 Financial Overview
  96.       5.2.1.2 Products Offered
  97.       5.2.1.3 Key Developments
  98.       5.2.1.4 SWOT Analysis
  99.       5.2.1.5 Key Strategies
  100.     5.2.2 Merck & Co. (US)
  101.       5.2.2.1 Financial Overview
  102.       5.2.2.2 Products Offered
  103.       5.2.2.3 Key Developments
  104.       5.2.2.4 SWOT Analysis
  105.       5.2.2.5 Key Strategies
  106.     5.2.3 Roche (US)
  107.       5.2.3.1 Financial Overview
  108.       5.2.3.2 Products Offered
  109.       5.2.3.3 Key Developments
  110.       5.2.3.4 SWOT Analysis
  111.       5.2.3.5 Key Strategies
  112.     5.2.4 Pfizer (US)
  113.       5.2.4.1 Financial Overview
  114.       5.2.4.2 Products Offered
  115.       5.2.4.3 Key Developments
  116.       5.2.4.4 SWOT Analysis
  117.       5.2.4.5 Key Strategies
  118.     5.2.5 AstraZeneca (US)
  119.       5.2.5.1 Financial Overview
  120.       5.2.5.2 Products Offered
  121.       5.2.5.3 Key Developments
  122.       5.2.5.4 SWOT Analysis
  123.       5.2.5.5 Key Strategies
  124.     5.2.6 Novartis (US)
  125.       5.2.6.1 Financial Overview
  126.       5.2.6.2 Products Offered
  127.       5.2.6.3 Key Developments
  128.       5.2.6.4 SWOT Analysis
  129.       5.2.6.5 Key Strategies
  130.     5.2.7 Eli Lilly and Company (US)
  131.       5.2.7.1 Financial Overview
  132.       5.2.7.2 Products Offered
  133.       5.2.7.3 Key Developments
  134.       5.2.7.4 SWOT Analysis
  135.       5.2.7.5 Key Strategies
  136.     5.2.8 Regeneron Pharmaceuticals (US)
  137.       5.2.8.1 Financial Overview
  138.       5.2.8.2 Products Offered
  139.       5.2.8.3 Key Developments
  140.       5.2.8.4 SWOT Analysis
  141.       5.2.8.5 Key Strategies
  142.     5.2.9 Amgen (US)
  143.       5.2.9.1 Financial Overview
  144.       5.2.9.2 Products Offered
  145.       5.2.9.3 Key Developments
  146.       5.2.9.4 SWOT Analysis
  147.       5.2.9.5 Key Strategies
  148.   5.3 Appendix
  149.     5.3.1 References
  150.     5.3.2 Related Reports
  151. 6 LIST OF FIGURES
  152.   6.1 MARKET SYNOPSIS
  153.   6.2 US MARKET ANALYSIS BY APPLICATION
  154.   6.3 US MARKET ANALYSIS BY MECHANISM OF ACTION
  155.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  156.   6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  157.   6.6 US MARKET ANALYSIS BY TREATMENT SETTING
  158.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  159.   6.8 RESEARCH PROCESS OF MRFR
  160.   6.9 DRO ANALYSIS OF HEALTHCARE
  161.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  162.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  163.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  164.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  165.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  166.   6.15 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE)
  167.   6.16 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion)
  168.   6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  169.   6.18 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  170.   6.19 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
  171.   6.20 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
  172.   6.21 HEALTHCARE, BY TREATMENT SETTING, 2024 (% SHARE)
  173.   6.22 HEALTHCARE, BY TREATMENT SETTING, 2024 TO 2035 (USD Billion)
  174.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  175. 7 LIST OF TABLES
  176.   7.1 LIST OF ASSUMPTIONS
  177.     7.1.1
  178.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  179.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  180.     7.2.2 BY MECHANISM OF ACTION, 2026-2035 (USD Billion)
  181.     7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  182.     7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
  183.     7.2.5 BY TREATMENT SETTING, 2026-2035 (USD Billion)
  184.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  185.     7.3.1
  186.   7.4 ACQUISITION/PARTNERSHIP
  187.     7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Oncology
  • Autoimmune Disorders
  • Infectious Diseases
  • Transplant Rejection
  • Other Applications

Healthcare By Mechanism of Action (USD Billion, 2026-2035)

  • CTLA-4 Inhibitors
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • Combination Therapies
  • Other Mechanisms

Healthcare By Route of Administration (USD Billion, 2026-2035)

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular
  • Other Routes

Healthcare By Patient Demographics (USD Billion, 2026-2035)

  • Age Groups
  • Gender
  • Ethnicity
  • Comorbidities
  • Socioeconomic Status

Healthcare By Treatment Setting (USD Billion, 2026-2035)

  • Hospital
  • Outpatient Clinic
  • Home Care
  • Research Institutions
  • Other Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓